Timothy M. Fan, DVM, PhD, DACVIM (Oncology) – University of Illinois
Daiki Kato, DVM, PhD – The University of Tokyo
Takayuki Nakagawa, DVM, PhD – The University of Tokyo
Investigating the immune and cytoreductive activities of gilvetmab alone and in combination with indoleamine 2,3-dioxygenase inhibition in canine urothelial carcinoma of the bladder.

Yoshimi Iwaki, DVM, MS, DACVIM & DAiCVIM (Oncology) – University of Missouri
Jeffrey N. Bryan, DVM, MS, PhD, DACVIM (Oncology) – University of Missouri
Adjuvant gilvetmab treatment for completely resected stage III canine pulmonary carcinomas.

Tiffany Martin, D.V.M., M.S., Diplomate ACVR (Radiation Oncology) – Colorado State University
Kristen Weishaar, D.V.M., M.S., Diplomate ACVIM (Oncology) – Colorado State University
Doug Thamm, V.M.D., Diplomate ACVIM (Oncology) – Colorado State University
Combination of hypofractionated radiation therapy and gilvetmab for the treatment of regionally extensive cutaneous or subcutaneous mast cell tumors in dogs.

Kristen Weishaar, D.V.M., M.S., Diplomate ACVIM (Oncology) – Colorado State University
Doug Thamm, V.M.D., Diplomate ACVIM (Oncology) – Colorado State University
Combination therapy with gilvetmab and toceranib in dogs with measurable mast cell disease.

Chelsea Tripp, DVM, MS, DACVIM (Oncology) – Owner, Bridge Animal Referral Center, Edmonds, WA
Mark J. Mamula, PhD., Professor of Medicine – Yale Cancer Center
Hester A. Doyle, PhD., Research Scientist – Yale University School of Medicine
Natalia Shulzhenko, M.D., PhD., Associate Professor – Oregon State University, Carlson College of Veterinary Medicine
Immunotherapy in the Treatment of Canine Hemangiosarcoma.